U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07600151) titled 'Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma' on April 26.
Brief Summary: This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.
Study Start Date: Dec. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Myeloma Multiple
Myeloma
Intervention:
DRUG: Etentamig
Administered per the protocol
DRUG: Isatuximab
Administered per the protocol
DRUG: Bortezomib + Lenalidomide + Dex...